ArticleCell biomaterials2026
Biomaterial-Enabled
Sharda Pandit, S Abbey Oliver, Emily Joe, Yevgeny Brudno
Abstract read
In one paragraphArticle in Cell biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Sharda PanditDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Chapel Hill, NC, USA.
S Abbey OliverDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Chapel Hill, NC, USA.
Emily JoeDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Chapel Hill, NC, USA.
Yevgeny BrudnoDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Chapel Hill, NC, USA.
Funding
Research Project 3: Biomaterials to Generate and Enhance CAR NK T Cell Efficacy for GBMP01CA298971 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Kristy M Ainslie · 2026 to 2026
$5.1MBiomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell ProductionR37CA260223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Yevgeny Brudno · 2021 to 2026
$2.5MBioinstructive Scaffolds for Potent and Affordable CAR-T Cell Therapy Against Brain TumorsR01CA278961 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Yevgeny Brudno · 2023 to 2026
$1.9MBiomaterial Scaffolds for In Vivo CAR T Cell ManufactureR21CA277018 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BRUDNO, YEVGENY · 2023 to 2024
$371kImage-guided, ultrasound-enhanced long-term intracranial drug deliveryR21CA246414 · NCI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI BRUDNO, YEVGENY, DAYTON, PAUL A · 2020 to 2021
$369kNCI NIH HHS P01 CA298971NCI NIH HHS R01 CA278961NCI NIH HHS R21 CA246414NCI NIH HHS R21 CA277018NCI NIH HHS R37 CA260223
6 · The paper itselfAbstract
T cell therapies have transformed treatment for previously intractable diseases. However, their full potential remains constrained by reliance on
Identifiers
PMID42872159
PMCPMC13660788
What OpenQuestion holds
Textmetadata
Read underepoch 390